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Abstract MicroRNAs (miRNAs) are short, non-coding
RNAs that have emerged as key post-transcriptional regula-
tors in a wide variety of organisms and critical cellular
processes. Because any one miRNA can regulate the expres-
sion of a distinct set of genes, differential miRNA expression
can shape the repertoire of proteins that are actually expressed
during development, differentiation, or disease. To understand
what goes wrong when a cell becomes transformed requires
knowledge of the processes that ensure normal development.
It is now clear that miRNAs may act as oncogenes and/or
tumor suppressors within gene regulatory networks, thereby
contributing to the development of cancer. Mast cells are long-
lived cells, widely distributed throughout vascularized tissues,
in particular near surfaces that are exposed to the environment
(such as skin, airways, and the gastrointestinal tract), where
they contribute to bacterial clearance, enhancement of adap-
tive immune responses, modulation of inflammation, and the
degradation of toxic peptides and venoms. Here we review
current knowledge in the field of mast-cell differentiation and
disease in humans and mice and discuss future directions and
links between mast-cell differentiation, oncogenic transfor-
mation, and microRNAs as well as possible new points of
entry for therapeutic intervention.
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MicroRNAs (miRNAs) are a class of small, non-coding
RNAs found in organisms ranging from nematodes to
humans and even viruses. They function mostly as
endogenous translational repressors of protein-coding
genes by binding to target sites in the 30 untranslated region
(30 UTR) of messenger RNAs. miRNAs are derived from
short hairpins of 60–70 nt (pre-miRNAs) that are cleaved
in the nucleus from longer primary transcripts (pri-miR-
NAs) by the Microprocessor complex, which includes the
RNAse III endonuclease Drosha. Pre-miRNAs are exported
to the cytoplasm, where the mature *22-nt miRNA is
excised by Dicer and loaded onto the RNA-induced
silencing complex (RISC). The miRNA-charged RISC
binds to the 30 UTR of target mRNAs and catalyzes mRNA
translational inhibition, destabilization, or degradation
(reviewed in Kanellopoulou and Monticelli 2008; Kim
et al. 2009).
Cells in the mammalian hematopoietic system express a
multitude of miRNA species which may or may not be
shared between different cell types or development stages,
but only a few of which are specific to the hematopoietic
system (Monticelli et al. 2005; Neilson et al. 2007; Wu
et al. 2007). The generation of the immune system from
hematopoietic stem cells involves ordered events of lineage
commitment, differentiation, proliferation, and cell migra-
tion. Within such processes, miRNAs appear ideally suited
to adjust protein concentrations rapidly in cells, allowing
complex cellular transitions to subsequent developmental
and activation stages. Accordingly, certain miRNAs are
expressed in a stage-specific fashion (Monticelli et al.
2005; Neilson et al. 2007; Wu et al. 2007) and miRNA
control has recently emerged as a critical regulatory prin-
ciple in the mammalian immune system. Indeed, it was
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shown that genetic ablation of the miRNA machinery
(Chong et al. 2008; Muljo et al. 2005) as well as loss or
deregulation of certain individual miRNAs severely com-
promised immune development and led to immune
disorders (reviewed in Kanellopoulou and Monticelli 2008;
Xiao and Rajewsky 2009). With the recent identification of
hundreds of genes that produce non-coding RNA tran-
scripts with no significant open reading frame, it has
become evident that the genomic complexity of any cell
is far greater than expected (reviewed in Pipkin and
Monticelli 2008). Consistent with the discovery that miR-
NAs modulate gene expression, altered miRNA expression
has been found to affect cancer development. By nega-
tively regulating proto-oncogenes, miRNAs could act as
tumor suppressors; conversely, by inhibiting tumor sup-
pressors, miRNAs could function as oncogenes. Indeed,
both increased and decreased miRNA abundance has been
observed in cancer cells compared with normal tissue.
Mast cells are cells of the innate immune system that
reside in most tissues of the body and derive from hema-
topoietic precursors in the bone marrow. Mast cells
function as effector and immunoregulatory cells in IgE-
associated allergic disorders as well as in certain innate and
adaptive immune responses (Kalesnikoff and Galli 2008).
Abnormal, dysregulated, and clonal accumulation of mast
cells gives rise to disorders such as mastocytosis. These
disorders can have a clinical course variably ranging from
asymptomatic for years to highly aggressive and rapidly
devastating. Within this scenario, since it is now clear that
miRNAs can act as oncogenes, and also contribute to the
normal regulation of most systems and pathways so far
analyzed, it is tempting to hypothesize that miRNAs may
also contribute to the uncontrolled growth of mast cells or
their progenitors. Here we review current knowledge in the
field, focusing, when possible, on human mast cells,
although due to the paucity of available data, our conclu-
sions by necessity will depend in part on results of studies
using non-human mast cells.
Distribution, Differentiation, and Activation
of Mast Cells
Mast cells are long-lived cells derived from hematopoietic
progenitor cells. They usually do not circulate in mature
form in the blood, as their differentiation and maturation
take place in the tissues where they will ultimately reside;
nevertheless, upon stimulation, mast cells can reenter the
cell cycle and proliferate. Specifically, an increase in
number or tissue distribution as well as changes in phe-
notypical characteristics of mast cells can occur during T
helper 2 (Th2) lymphocyte responses (Galli et al. 2008a).
In mammals and other vertebrates, mast cells are widely
distributed throughout vascularized tissues, particularly
beneath epithelia and in close proximity to blood vessels,
nerves, smooth muscle cells, mucus-producing glands, and
hair follicles (Galli et al. 2005b), and are especially
prominent in areas exposed to the environment (skin,
mucosal airways, and the gastrointestinal tract), where
pathogens and allergens are frequently encountered. Mast
cells are critical effector cells in allergic disorders; how-
ever, recent studies have shown that these cells are
heterogeneous and can produce an array of pro- and anti-
inflammatory mediators, act as antigen-presenting cells,
and express a spectrum of co-stimulatory molecules, indi-
cating that mast cells are far more functionally diverse than
previously imagined and can function as immunoregula-
tory cells (Benoist and Mathis 2002; Galli et al. 2005a, b).
Mast cells can participate in a wide variety of physio-
logical and pathological processes as a result of their
activation through a variety of receptors. However, two of
the best-studied receptors expressed on differentiated mast
cells are the high-affinity IgE receptor (FceRI) and c-Kit
(Fig. 1). Both of these receptors have important roles in the
differentiation, survival, proliferation, and function of mast
cells (reviewed in Kalesnikoff and Galli 2008). In partic-
ular, mast cells are well known as key effector cells in IgE-
associated immune responses. In appropriately sensitized
hosts, encounter with a specific antigen will induce mast
cells to undergo activation dependent on specific IgE
bound to the FceRI. The cytoplasm of mature mast cells is
characteristically full of granules containing preformed
mediators such as proteoglycans, proteases, and histamine.
Upon cell activation, these preformed mediators are
released into the extracellular milieu. The chemical prop-
erties of the granules can be used to stain the cells with
toluidine blue or other similar stains that will turn char-
acteristically purple in the presence of the content of the
granules (Fig. 1).
The types and properties of the endopeptidases stored in
the granules vary with the organism and the final tissue
where the mast cell will ultimately reside and terminate its
differentiation. Based on the expression of these enzymes,
human mast cells have been broadly classified into two
major classes: those expressing tryptase only (this type of
cells is called also MCT), which tend to be located in the
mucosa of organ systems, and those expressing both chy-
mase and tryptase (MCTC), which tend to be abundant in
the dermis (Fig. 1).
Human mast cells can be differentiated in vitro from
precursors derived from cord blood or bone marrow as well
as from hematopoietic progenitors separated from periph-
eral blood (Holm et al. 2008). While the main growth
factor for rodent mast cells is IL-3, human mast cells seem
to be relatively more IL-3 independent and require more
strictly SCF (the ligand for the c-Kit receptor) for their
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growth and survival (Galli et al. 2008b; Saito et al. 2006).
An example of the resulting phenotype of human mast cells
differentiated in vitro in our lab is shown in Fig. 1 (Deho’
and Monticelli, unpublished). Interestingly, these in vitro
differentiated cells contained tryptase in their cytoplasmic
granules, but not chymase, indicating an MCT-like phe-
notype that is considered still rather immature (Galli et al.
2008a). Cultured human mast cells with an MCTC pheno-
type (i.e. expressing a high amount of chymase as well as
tryptase) can be obtained starting from cord blood pre-
cursors treated with IL-4 in the latest stages of the
differentiation process (Toru et al. 1998a), indicating a
possible pathway of development from tryptase single-posi-
tive into tryptase/chymase double-positive cells and
suggesting that this maturation process is promoted by IL-4.
Murine mast cells can be easily differentiated not only
from bone marrow, but also from embryonic stem cells
(Garrington et al. 2000; Monticelli et al. 2004; Tsai et al.
2000); these embryonic stem-derived mast cells represent a
very important tool to study the effect of genetic alteration
in mast-cell differentiation and function. Recently, murine
as well as human differentiated adult cells have been
reprogrammed directly to pluripotency by ectopic expres-
sion of four transcription factors (Oct4, Sox2, Klf4, and
Myc) to yield induced pluripotent stem (iPS) cells (Park
et al. 2008; Takahashi and Yamanaka 2006). Patient-spe-
cific iPS cells hold great therapeutic potential: indeed, it
has been recently shown that on correction of the genetic
defect, somatic cells from Fanconi anemia patients can be
reprogrammed to pluripotency to generate patient-specific
iPS cells (Raya et al. 2009). Most importantly, Raya and
colleagues showed that genetically corrected Fanconi
anemia-specific iPS cells can give rise to hematopoietic
progenitors of the myeloid and erythroid lineages that are
phenotypically normal, i.e. disease free. In order to study
the effect of genetic alteration in human mast-cell differ-
entiation and function, a possibility would be to obtain iPS
cells from patients with altered mast-cell functions (which
in principle could range from allergic inflammation to
aggressive mastocytosis) and study the differentiation and
function of these cells in vitro.
Mast Cells in Inflammation
Mast cells are mostly famous for their association with
acute manifestations of hypersensitivity reactions, allergic
asthma, allergic rhinitis, and anaphylaxis. Following acti-
vation through the IgE receptor FceRI, mast cells not only
release mediators that are pre-stored in the cytoplasmic
granules, but also initiate de novo synthesis and release
of several lipid-derived molecules as well as cytokines,
chemokines, and growth factors. These products may be
released when mast cells are activated via IgE- or
IgG-dependent mechanisms and may also be produced
in response to stimulation by bacterial products through
Toll-like receptors. A number of potential functions have
been associated with various mast-cell proteases, including
human ileum mucosa




























Fig. 1 Human mast cells differentiated in vitro express specific mast-
cell markers. a Committed hCD133? progenitors were separated from
peripheral blood and differentiated in vitro for 5 weeks. In the first
3 weeks the cells were cultured in Stem Span serum-free medium
supplemented with hIL-3, hIL-6, and hSCF, while in the last 2 weeks
the cytokine cocktail was changed to hIL-6, hSCF, and hIL-4. The
cells were than stained for the surface mast-cell markers FceRI and
c-KIT (red lines; in grey the negative controls for the staining). b The
same cells as in a were also stained with toluidine blue to visualize
the cytoplasmic granules of differentiated mast cells (in purple, as
opposed to the blue of the nuclei and the pale blue of the cytoplasm of
other cell types). c Top The same cells as in a were stained for the
enzymes tryptase (red) and chymase (green), that are normally
present in cytoplasmic granules, while the nuclei were counterstained
with DAPI (blue). The in vitro differentiated cells turned out to be
tryptase? and chymase-. Bottom As a control for the stainings, a
tissue sample from human ileum mucosa was used. Mast cells that are
tryptase? are red, while those that are both tryptase? and chymase?
are yellow. The numbers at the top left corner indicate the
magnification used
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bronchoconstriction, and degradation of fibrinogen and
extracellular matrix proteins.
Several studies have shown that mast cells can produce an
array of pro- and anti-inflammatory mediators and express a
spectrum of co-stimulatory molecules, indicating that mast
cells are functionally diverse and can function as immuno-
regulatory cells (Benoist and Mathis 2002; Galli et al.
2005a, b). Indeed, mast cells can exert positive or negative
immunomodulatory effects on other immune cells by influ-
encing their recruitment, survival, development, phenotype,
or function and thereby enhance or suppress the initiation,
magnitude, and/or duration of immune responses (reviewed
in Galli et al. 2008a). Molecules produced by mast cells with
possible immunomodulatory functions include members
of the tumor necrosis factor (TNF) family as well as cyto-
kines that can influence T-cell functions such as IL-4, IL-5,
IL-6, and IL-13. Mast cells can also mediate negative
immunomodulatory functions in vivo by producing IL-10
(Grimbaldeston et al. 2007). Moreover, mast cells express
MHC class I and II molecules on their surface and they have
been reported to be able to process and present antigen in vitro
(Galli et al. 2008b). However, the in vivo relevance of some of
these molecules remains to be determined. It also needs to be
highlighted that many of these studies were performed on
murine mast cells and it is now clear that these may not always
predict the human mast-cell response. For example, while
mouse mast cells produce significant amounts of IL-4, human
mast cells may not (Toru et al. 1998b).
Although blood monocytes, tissue macrophages, and
Kupffer cells are the best-known sources of TNF, mast
cells (at least in the mouse) are the only cell type capable of
storing pre-synthesized TNF. Because of this unique
capability, mast cells provide the only readily available
source of TNF within peripheral tissues during the early
course of infection. During infection, peripheral tissue mast
cells regulate lymph node hypertrophy through the rapid
secretion of TNF (McLachlan et al. 2003). Interestingly, it
has recently been shown that peripheral murine mast cells,
upon activation, release stable submicrometer heparin-
based particles containing TNF and other proteins. These
insoluble complexes increase the normally short half-life of
TNF, enter lymphatic vessels, and rapidly traffic to the
draining lymph nodes. This physiological drug delivery
system facilitates communication between peripheral sites
of inflammation and remote secondary lymphoid tissues
(Kunder et al. 2009).
Excessive or inappropriate mast-cell activation also
contributes to the development of certain allergic or auto-
immune diseases, which are mediated by allergen- or
autoantigen-specific effector T cells (Galli et al. 2005b).
No clinically available pharmacological agents can spe-
cifically inhibit either mast-cell degranulation or mast-cell
mediator release. Understanding these processes in human
cells could help in developing mast-cell inhibitors of
selective mediator release with novel therapeutic applica-
tions (Theoharides et al. 2007). Apart from this ‘‘negative’’
role, it is important to remember that mast cells reside at
the crossroads between the external environment, the blood
vasculature, and the lymphatic system. They are therefore
ideally situated to orchestrate events during the earlier
stages of immune responses and it seems likely that this is
their physiological role in mammalian biology.
Mast-Cell Diseases
Although mast cells have been mostly studied for their role
in allergic disorders, they have also been implicated in
a range of other diseases, including diabetes (Geoffrey
et al. 2006; Liu et al. 2009), obesity and angiogenesis (Liu
et al. 2009), experimental autoimmune encephalomyelitis
(Tanzola et al. 2003), and rheumatoid arthritis (Eklund
2007). Mastocytosis is a mast-cell disorder characterized by
dysregulated and clonal accumulation of mast cells and/or
mast-cell products in organs such as the skin, gastrointesti-
nal tract, bone marrow, liver, spleen, and lymph nodes,
although any tissue may be affected. Mastocytosis can occur
at any age and the exact prevalence is unknown. There are
many variants of this disease, presenting a wide range of
symptoms and prognoses. The two main variants are clas-
sified as cutaneous, most common in children, and systemic
mastocytosis and they are now believed to be in part
dependent on somatic mutation or inherited polymorphisms.
In cutaneous mastocytosis there is no evidence of systemic
involvement and three major variants are now recognized:
(i) urticaria pigmentosa/macuolopapular mastocytosis is the
most frequent form and in children the lesions are usually
larger and papular. In this variant, mast cells assume a
characteristic spindle shape and fill the papillary dermis. In
adults the lesions are red and disseminated. (ii) Diffuse
cutaneous mastocytosis is less frequent than the previous
variant and is present almost exclusively in children. The
skin is thick and may have a peau chargine (orange peel)
appearance. (iii) Mastocytoma of the skin occurs as a single
lesion exclusively in infants and without predilection of site.
Vice versa, systemic mastocytosis is characterized by the
involvement of at least one extracutaneous organ, even
without skin lesions. There are many variants of systemic
mastocytosis, including indolent systemic mastocytosis,
bone marrow mastocytosis, mast-cell leukemia, and mast-
cell sarcoma (WHO 2008). Prognosis depends on the disease
category and currently no specific cure is available. In
children, cutaneous mastocytosis usually has a favorable
outcome and may regress spontaneously. In adults, however,
cutaneous lesions do not regress and are often associated
with systemic mastocytosis, usually the indolent variant.
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Patients with aggressive diseases, including mast-cell leu-
kemia, survive only a few months, whereas patients with
indolent systemic mastocytosis have a normal life expec-
tancy (WHO 2008).
Although some genetic alterations in mastocytosis have
been described (for example, the D816V gain-of-function
mutation in the c-KIT proto-oncogene), little is known
concerning pathogenetic factors that contribute to the
development of disease variants and disease progression.
Additional defects, that remain to be identified, are likely
to contribute to the uncontrolled growth of mast cells and/
or their progenitors and to the resulting adverse clinical
course (Metcalfe 2008; Valent et al. 2005).
Allergic disorders, such as anaphylaxis, hay fever, eczema,
and asthma, afflict roughly 25% of people in the developed
world. Asthma is a complex disease of the airways whose
incidence, morbidity, and mortality have increased dramati-
cally over the past two decades and continue to do so,
particularly in industrialized countries. In atopic asthmatics,
the immune system responds to harmless environmental
allergens which are typically ignored by non-atopic immune
systems. Key to the development of asthma is the priming of
allergen-specific CD4? T lymphocytes and their differentia-
tion to a Th2 phenotype. These cells orchestrate atopic
asthmatic inflammation through the secretion of cytokines,
particularly IL-4, IL-5, and IL-13, of which IL-4 in particular
drives IgE production by B cells. Following such sensitiza-
tion, subsequent exposure to the specific allergen initiates a
secondary response characterized by rapid onset of mucosal
edema, increase in airway smooth muscle tone, and airway
narrowing. This response is induced by IgE-mediated mast-
cell degranulation and the associated release of inflammatory
mediators, including histamine, prostaglandins, and leukotri-
enes. While early- and late-phase reactions to an allergen can
resolve fully without treatment, chronic allergic inflammation
is a persistent inflammation that occurs at sites of repeated
allergen exposure and can lead to altered functions of the
affected organs (Tillie-Leblond et al. 2005). It is therefore
important to understand the characteristics and consequences
of acute and chronic allergic inflammation, and in particular to
explore how mast cells can contribute to several features of
this immunological reactivity (Galli et al. 2008b). Moreover,
while a role for miRNAs has been clearly established for the
development and functions of other cell types and for diseases
such as cancer, their role in mast-cell physiology as well as in
asthma remains to be elucidated.
Mast Cells and miRNAs
The molecular network that regulates mast-cell differentia-
tion and function has not been investigated as widely as it has
been in other hematopoietic cells. There are still many
mechanisms of regulation that need to be fully elucidated to
understand how external stimuli can lead to an appropriate
physiological response by mast cells. Such information could
be used to determine potential therapeutic targets for the
control of mast-cell activation in inflammatory diseases,
allergy, and asthma. Our group has already shown that some
selected miRNAs might be important for murine mast-cell
differentiation (Monticelli et al. 2005) as well as the prolif-
eration of differentiated mast cells (Mayoral et al. 2009).
Specifically, we identified a family of two miRNAs,
miR-221-222, which is upregulated following activation of
differentiated murine bone marrow-derived mast cells
(BMMCs) (Mayoral et al. 2009). This is one of the first
examples of miRNAs whose expression changes as a result
of acute cell activation, as opposed to cell differentiation, and
implies a role for miRNAs not only during cell differentiation
and to maintain cell identity, but also in cellular effector
functions and/or proliferation. Indeed, using both bioinfor-
matics and experimental approaches, we characterized some
transcriptional requirements (in particular, we suggested
involvement of the transcription factors NF-jB, NFAT, and
PLZF) for the miR-221-222 gene, and through analysis of the
pattern of DNaseI hypersensitivity we identified potential
cis-regulatory regions that might control the expression of
miR-221-222 in mast cells. Furthermore, by overexpressing
miR-221-222 individually or in combination, we found that
these two miRNAs cooperate in regulating cell cycle and cell
proliferation in mast cells. Interestingly, overexpression of
miR-221-222 had a modest effect on the expression of the
known target p27Kip1; we showed that such partial effect on
p27Kip1 was due to a splice variant of p27Kip1 that does not
contain miR-221-222 binding sites in its 3’ UTR. Finally,
cell-cycle regulation is likely to be a more general effect of
miR-221-222, as transgenic expression of miR-221-222 from
BAC clones in murine embryonic stem cells dramatically
reduced cell proliferation and severely impaired their accu-
mulation. Our study provided further insights into miR-221-
222 transcriptional regulation as well as evidence that
miR-221-222 regulates cell-cycle checkpoints in mast cells in
response to acute activation stimuli. Following up on those
studies, by lentivirally transducing primary BMMCs we could
show that miR-221-222 are not only important in mast-cell
proliferation, but have pleiotropic effects on essential mast-cell
processes such as migration, survival, and homing (Mayoral
and Monticelli, unpublished). Nevertheless, a direct link
between mast cells, miRNAs, and mast-cell diseases remains to
be uncovered, especially concerning the human system.
miRNAs in Therapy?
The importance of miRNAs in fine-tuning gene expression is
highlighted by the finding that changes in the abundance of a
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single miRNA can affect the levels of expression of hun-
dreds of proteins (Baek et al. 2008; Selbach et al. 2008). It is
therefore not surprising that a single dysregulated miRNA
can have profound effects on the state of the cell. There are
indeed now numerous examples linking dysregulated
expression of miRNAs to cancer (Croce 2009; Kanellop-
oulou and Monticelli 2008) and miRNAs are increasingly
viewed as potential therapeutic targets (see also Fig. 2).
While restoring miRNA expression can be used in cases of
miRNAs that function as onco-suppressors, it is important to
be able to dampen miRNA expression or block their function
in cases in which their overexpression favors cellular
oncogenic transformation (i.e. ‘‘onco-miRs’’). To achieve
this, new technologies are emerging (Fig. 2). Such tech-
nologies provide a versatile tool to investigate miRNA
functions utilizing artificial systems to either upregulate or
ablate miRNA expression or to affect the expression of a
target mRNA by means of the RNA interference (RNAi)
pathway. Double-stranded RNA oligonucleotides (miRNA
‘‘mimics’’) or antisense oligonucleotides to the miRNA
sequence (20-O-methyl oligonucleotides, or locked nucleic
acids) can be effectively used to upregulate or block the
expression of miRNAs in a wide variety of cells and sys-
tems. The drawback with using oligos is that the system
is intrinsically transient. Other systems to overexpress
or block long-term miRNA function use vectors based on
lentiviruses, adenoviruses, and retroviruses. Vectors to
overexpress miRNAs usually contain the miRNA sequence
plus *200 bp of genomic sequence on each side to ensure
proper processing. Instead, vectors to inhibit miRNA func-
tions are called decoys, sponges, or erasers and usually
contain multiple miRNA target sites cloned downstream
from a reporter gene expressed from a strong promoter
(Fig. 2), often of viral origin (Haraguchi et al. 2009). The
overexpression of artificial miRNA target sites in the cells
prevents the miRNA of choice from regulating its natural
targets (Brown and Naldini 2009; Brown et al. 2006).
Finally, RNAi is the process of mRNA degradation that is
induced by double-stranded RNA in a sequence-specific
manner. The specificity and effectiveness of RNAi makes it
a valuable research tool: synthetic dsRNA introduced into
cells can down-modulate the expression of specific genes of
interest (Siomi and Siomi, 2009), while miRNA-based
vectors can be used to express short hairpin RNAs to reduce
the levels of expression of selected oncogenes through the
RNAi pathway (Chang et al. 2006). Recently, Kota et al.
(2009) demonstrated in a mouse model of liver cancer that
ectopic expression of a single miRNA, miR-26a, can reverse
disease progression. In this particular study, the delivery of
an miR-26a-expressing construct in vivo was achieved by
using an adeno-associated virus (AAV) vector. AAV vectors
are particularly suitable as gene therapy vectors as they can
be produced in large quantities and do not integrate into the
host genome. This means that they will eventually be
eliminated, thereby minimizing the potential of vector-
mediated toxicities. This report represents an important step
toward the potential application of miRNA-based therapy
for the treatment of cancers. In particular, correction of a
genetic defect in mast-cell diseases by altering miRNA
levels or by using miRNA-based technology holds promise
for the correction of such diseases.
Conclusions
Mastocytosis may occur at any age, familial occurrence is
unusual, and the exact prevalence of mastocytosis and its
variants is unknown. Moreover, treatment of mastocytosis
is based on amelioration of symptoms with pharmacolog-
ical agents that inhibit the actions of mediators identified as
mast cell derived, especially histamine and leukotrienes,
but so far no standard therapy for patients with aggressive
forms of disease has been defined (Valent et al. 2005;
WHO 2008). It is therefore essential to uncover some of the
molecular networks that may be at the basis of mastocy-
tosis development and to provide further tools for diagnosis
and prognosis. Ultimately, we look forward to under-
standing how perturbation of miRNA-related networks
A Modulating miRNA expression:









Fig. 2 Vectors used to modulate miRNA or mRNA expression.
a Schematic representation of vectors commonly used to modulate
miRNA levels to enhance (?) or silence (-) miRNA expression. (?)
Vector a vector to overexpress miRNAs requires a promoter (usually
Pol II dependent) (arrow) and the miRNA sequence with *200 bp of
genomic sequence on each side to ensure proper processing. In this
and in all the other vectors shown, a reporter gene can be used to
identify and/or select transduced cells. (-) Vector a vector to
functionally ablate the miRNA of choice is made by cloning several
miRNA binding sites downstream from a reporter gene. Upon
transcription, this gives rise to synthetic miRNA targets, therefore
preventing the miRNA of choice from regulating its natural targets.
b Vectors similar to the ones described in a can be used also to
express short hairpin RNA (shRNA) for silencing a specific
oncogenic mRNA through the RNAi pathway
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may apply to disease conditions, with the hope that they
may lend diagnostic insight or lead to novel entry points for
therapeutic intervention.
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